China Biologic Receives Higher Counter Bid From Investor Group Led By Ex-CEO

Login to View

China Biologic Products Holdings Inc, a leading plasma-based biopharmaceutical company in China, received a $3.9 billion counter offer from an investor consortium led by its former CEO, the group said in a release on Monday.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in